Promotion of the Selection and Use of Generic Drugs
First written in FY2016. 16 of 23 entries say "Restated". Latest entry: 2026-09-17.
No other company in this theme has enough history to compare yet.
- 2026-09-17Cited as achievedManagement plan
「For the generic drug ratio, we achieved 94.3% against the target of at least 90%.」
The Company cited the achievement of a 94.3% generic drug ratio against the previous KPI of at least 90%. - FY2026Disclosure of a Generic Drug KPIAnnual report
「・Group average generic medicine ratio of 90% or more」
We disclosed a materiality KPI of a group-wide average generic medicine ratio of 90% or more for the selection and promotion of generic medicines. - FY2026-H1AdvancedAnnual report
「We are focusing on measures to ensure that medicines are delivered to patients even when they are out of stock. Recently, approximately 90% of medicines were delivered to patients even during stockouts at the model stores and areas where these measures had been implemented, demonstrating measurable results.」
Regarding the stable supply of medicines, including generic medicines, we have demonstrated that approximately 90% were delivered to patients at model stores and in model areas even during stockouts. - FY2023Addition of measures to ensure stable supplyAnnual report
「Regarding supply disruptions caused by quality problems and other issues at generic medicine manufacturers, we have established a system that uses the Group's extensive store network to ensure that medicines are reliably delivered to patients.」
In addition to the institute's selection and promotion of generic medicines, we disclosed a system for addressing supply disruptions caused by quality problems and other issues at manufacturers. - FY2023-Q3RestatedAnnual report
「② Promotion of generic drugs」
We continue to promote generic medicines as a pharmacy-management measure aimed at becoming a regular pharmacy of choice. - FY2022RestatedAnnual report
「We have continued to promote the expanded use of generic medicines and the adoption and promotion of electronic medication notebooks, as well as initiatives addressing self-medication and expanding businesses outside the health insurance system.」
We continue to expand and promote the use of generic medicines. - FY2022-Q2RestatedAnnual report
「We have continued to promote the community healthcare initiatives pursued to date, including home healthcare and institutional dispensing, the expanded use of generic drugs, and the adoption of electronic medication notebooks, as well as initiatives addressing self-medication and expanding businesses outside the national health insurance system.」
We continue to expand and promote the use of generic medicines. - FY2022-Q1RestatedAnnual report
「We have continued to promote the expanded use of generic medicines and the adoption and promotion of electronic medication notebooks, as well as initiatives addressing self-medication and expanding businesses outside the health insurance system.」
We continue to expand and promote the use of generic medicines. - FY2021AdvancedAnnual report
「We had achieved an 80% volume share for generic medicines as of the fiscal year ended May 2019. As of the end of May 2021, 184 stores were claiming Generic Medicine System Add-on 3, exceeding the plan, and the figure had risen further to 83.5% as of the end of the fiscal year ended May 2021.」
The volume share of generic medicines rose from 82.5% to 83.5%, while the number of stores claiming Generic Medicine System Add-on 3 reached 184. - FY2021-Q3RestatedAnnual report
「We have continued to promote the community healthcare initiatives pursued to date, including home healthcare and institutional dispensing, the expanded use of generic drugs, and the adoption of electronic medication notebooks, as well as initiatives addressing self-medication and expanding businesses outside the national health insurance system.」
We continue to expand and promote the use of generic medicines. - FY2021-Q2RestatedAnnual report
「We have continued to promote the community healthcare initiatives pursued to date, including home healthcare and institutional dispensing, the expanded use of generic drugs, and the adoption of electronic medication notebooks, as well as initiatives addressing self-medication and expanding businesses outside the national health insurance system.」
We continue to expand and promote the use of generic medicines. - FY2020AdvancedAnnual report
「We had achieved an 80% volume share for generic medicines as of the fiscal year ended May 2019. As of the end of May 2020, 145 stores were claiming Generic Medicine System Add-on 3, exceeding the plan, and the figure had risen further to 82.5% as of the end of the fiscal year ended May 2020.」
The volume share of generic medicines rose from 80% to 82.5% by the end of the fiscal year ended May 2020, while the number of stores claiming Generic Medicine System Add-on 3 reached 145. - FY2020-Q2RestatedAnnual report
「② Promotion of generic drugs」
Promotion of generic drugs continues as an initiative to develop family pharmacies. - FY2020-Q1RestatedAnnual report
「Traditional regional healthcare, including home healthcare and institutional dispensing, the expanded use of generic medicines, and the adoption and promotion of electronic medication notebooks」
We continue to expand and promote the use of generic medicines. - FY2019-Q3RestatedAnnual report
「② Promotion of generic drugs」
Promotion of generic drugs continues as an initiative to develop family pharmacies. - FY2019-Q1RestatedAnnual report
「② Promotion of generic drugs」
Promotion of generic drugs continues as an initiative to develop family pharmacies. - FY2018RestatedAnnual report
「Centered on our in-house research organization, the PharmaRise Pharmaceutical Information Research Institute, we select reliable generic drugs and are working to establish a system that can accommodate, to the greatest extent possible, requests from patients and medical institutions such as hospitals and clinics.」
We continue to select the generic medicines recommended by the institute and maintain the system for providing them. - FY2018-Q3RestatedAnnual report
「② Promotion of generic drugs」
Promotion of generic drugs continues as an initiative to develop family pharmacies. - FY2018-Q2RestatedAnnual report
「Working to expand the use of generic medicines and promote the adoption and use of electronic medication notebooks」
We have made the expanded use of generic medicines an ongoing business-management initiative. - FY2017-Q3RestatedAnnual report
「We are working to respond to changes in the business environment by further promoting the use of generic medicines and the adoption and promotion of electronic medication notebooks.」
We continue to promote the expanded use of generic medicines as a measure to respond to the business environment. - FY2017-Q2RestatedAnnual report
「② Promotion of generic drugs」
We continue to expand and promote the use of generic medicines as a measure to develop stores into patients' regular pharmacies. - FY2017-Q1RestatedAnnual report
「② Promotion of generic drugs」
Promotion of generic drugs continues as an initiative to develop family pharmacies. - FY2016First statedAnnual report
「Centered on our in-house research organization, the PharmaRise Pharmaceutical Information Research Institute, we select reliable generic drugs and are working to establish a system that can accommodate, to the greatest extent possible, requests from patients and medical institutions such as hospitals and clinics.」
The group promotes generic drugs through reliability assessments and the preparation of recommended product lists by its research institute.